title: UUUUUNU oligonucleotide inhibition of RNA synthesis in vaccinia virus cores.
abstract: Recent results from this laboratory demonstrated the ability of U5NU-containing oligonucleotides to stimulate premature termination of early gene transcription in vitro. Further studies on the oligonucleotide sequence and structural requirements for stimulating premature termination demonstrated that only oligonucleotides possessing ribouracil U9 with a phosphodiester linkage are active. Because an oligonucleotide as short as 9 bases serves as an effective stimulator of premature transcription termination, we reasoned that short U5NU-containing oligonucleotides might serve as efficacious anti-poxvirus agents because they would prevent the synthesis of full-sized early mRNA. To be useful in vivo, the oligonucleotides must not only be taken up by the infected cells, but also be able to enter the virus core, the site of early gene transcription, and retain their ability to stimulate premature termination. The ability of U9-containing oligonucleotides to inhibit virus core RNA synthesis was evaluated. The U5NU oligonucleotides exhibited a dramatic sequence-specific inhibition of core RNA synthesis, consistent with their ability to stimulate premature termination of early gene transcription. Moreover, the concentration of U5NU oligonucleotide required to exhibit half maximal inhibition of RNA synthesis was found to be less for a 9 mer RNA than it was for a 17 or 22 mer RNA. This suggests the possibility that the smaller oligonucleotides may have easier access to the core. This observation lends support to the notion that such oligonucleotides might serve as effective anti-poxvirus therapeutic agents.
authors.affiliation: Department of Biochemistry, School of Medicine and Biomedical Sciences, State University of New York, Buffalo, NY 14214, USA.
authors.forename: Mohamed Ragaa
authors.initials: MR
authors.lastname: Mohamed
authors.forename: Edward G
authors.initials: EG
authors.lastname: Niles
mesh_terms: D009154:Mutation; D009841:Oligonucleotides / Q000138:chemical synthesis / Q000235:genetics / Q000494:pharmacology*; D012367:RNA, Viral / Q000096:biosynthesis*; D014158:Transcription, Genetic; D014616:Vaccinia virus / Q000235:genetics / Q000502:physiology*; D014779:Virus Replication
chemical_list: D009841:Oligonucleotides; D012367:RNA, Viral